AviadoBio Ltd, a preclinical gene therapy company based in the UK, has appointed David Cooper as chief medical officer. Dr Cooper joins from uniQure Inc where he was head of clinical development, working to translate preclinical gene therapy assets to the clinic. Prior to this, he worked at Novo Nordisk A/S in the haemophilia and rare bleeding disorders space, contributing to clinical trial planning and execution and life cycle management of the company’s medicines.
Dr Cooper completed his doctor of medicine degree at Cornell University and trained as a neurosurgeon at the State University of New York Health Science Center, both in the US.
AviadoBio announced the appointment on 2 August 2022.
Copyright 2022 Evernow Publishing Ltd